CHIRON SECOND QUARTER EARNING EMERGENCE LEADS TO 10-3/4 GAIN IN AUGUST
Executive Summary
Chiron's profitable second quarter is swinging the weight of market opinion in its favor: surprisingly strong second quarter results contributed to a 10-3/4 point (13.6%) gain in August to carry the stock to 89-3/4. Cowen & Co., Salomon Brothers and Brown Brothers all upped their rating of the stock during August; according to Zacks Investment Research, 14 of 21 analysts rated Chiron a "strong buy" or "buy.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.